Biovaxys

BioVaxys Technology scientific advisor presents at highly-regarded European Congress of Immunology

Proactive Investors

BioVaxys confirms first clinical site for Phase I ovarian cancer vaccine trial in France

Proactive Investors

Biovaxys: May 8th, 2021 is World Ovarian Cancer Day (Ovarian, HPV Anti-Cancer Vaccine)

High Heal Diaries

BioVaxys announces completed synthesis of its pan-sarbecovirus vaccine candidate

Proactive Investors

Biovaxys says CoviDTH shows safety and tolerability in pathology and immunology evaluations

Proactive Investors

BioVaxys Technology's Viral and Oncology Vaccine Platforms 病毒和腫瘤疫苗平台 - GCFF Healthcare Event 線上醫療會議

BioVaxys Technology says Procare Health deal positions it as leading player in US women's healthcare

Proactive Investors

BioVaxys Technology (BIOV.C) Receives Positive FDA Response

BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys says bio-manufacturing partner BioElpida completes next phase of BVX-0918 production

Proactive Investors

One Unique Biotech Stock To Watch? Biovaxys CEO Interview

Departures Capital

Biovaxys Developing Anti-Cancer Vaccine for Ovarian and HPV Cancers

High Heal Diaries

BioVaxys's partner completes synthesis of recombinant SARS-CoV-2 s-protein for its two programs

Proactive Investors

BioVaxys Technology reveals latest findings on its haptenized SARS-CoV-2 s-spike protein vaccine

Proactive Investors

BioVaxys enters critical tumor cell supply agreement with Deaconess Research Institute

Proactive Investors

BioVaxys Technology Corp files US provisional patent application for pan-sarbecovirus vaccine

Proactive Investors

Biovaxys (BIOV.C) Founder & CEO James Passin talks about their tech, Covid & cancer treatment (Ep56)

BioVaxys acquires TAETSoftware to utilize Trial Adverse Events Tracker platform

Proactive Investors

BioVaxys announces finalized U.S. distribution agreement for Papilocare women's health treatment

Proactive Investors